Gainers
RAPT Therapeutics, Inc. (NASDAQ: RAPT) shares jumped 115.5% to settle at $40.02 on Monday as the company announced topline results from its Phase 1b trial of RPT193 as monotherapy for moderate-to-severe atopic dermatitis (AD).
X Financial (NYSE: XYF) today announced that Mr. Shaoyong (Simon) Cheng has been appointed as the Vice Chairman of the Board of Directors and has resigned as President of the Company with effect from May 24, 2021 and that Mr. Kan (Kent) Li has been appointed as President of the Company with effect from May 24, 2021.